Harvard Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 07, 2024 at 07:00 am EST
Share
Harvard Bioscience, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 28.15 million compared to USD 28.43 million a year ago. Net loss was USD 1.82 million compared to USD 1.67 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.04 a year ago.
For the full year, sales was USD 112.25 million compared to USD 113.34 million a year ago. Net loss was USD 3.42 million compared to USD 9.52 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.08 compared to USD 0.23 a year ago.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.